108 related articles for article (PubMed ID: 6420959)
1. Nonsteroid antiinflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients.
Kreis H; Chkoff N; Droz D; Noel LH; Tolani M; Descamps JM; Chatenoud L; Lacombe M; Crosnier J
Transplantation; 1984 Feb; 37(2):139-45. PubMed ID: 6420959
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
[TBL] [Abstract][Full Text] [Related]
3. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
4. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.
Norman DJ; Barry JM; Bennett WM; Leone M; Henell K; Funnell B; Hubert B
Am J Kidney Dis; 1988 Feb; 11(2):90-3. PubMed ID: 3124611
[TBL] [Abstract][Full Text] [Related]
5. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
[TBL] [Abstract][Full Text] [Related]
6. Serial monitoring of T-cell subset ratios with monoclonal antibodies in steroid- and antithymocyte globulin-treated patients with renal allotransplants.
Lewis RE; Kirchner K; Preuss T; Raju S; Krueger R; Cuchens M; Bower JD; Cruse JM
Clin Immunol Immunopathol; 1984 May; 31(2):241-53. PubMed ID: 6232027
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
Sollinger HW
Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
[TBL] [Abstract][Full Text] [Related]
8. Antithymocyte globulin in cadaver renal grafts: prophylaxis and antirejection therapy with three different preparations.
MacDonald AS; Belitsky P; Lannon SG; Cohen A; White J
Transplant Proc; 1982 Dec; 14(4):631-4. PubMed ID: 6762719
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
[TBL] [Abstract][Full Text] [Related]
10. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
11. Antithymocyte globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen.
Wechter WJ; Brodie JA; Morrell RM; Rafi M; Schultz JR
Transplantation; 1979 Oct; 28(4):294-302. PubMed ID: 388762
[TBL] [Abstract][Full Text] [Related]
12. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
[TBL] [Abstract][Full Text] [Related]
13. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
Schulz T; Kapischke M; Busing M
Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple rejection episodes with ALG or ATGAM after cadaveric renal transplantation.
Toledo-Pereya LH; Whitten J; Baskin S; McNichol L; Thavarajah K; Lin W
Bol Asoc Med P R; 1984 Jul; 76(7):293-6. PubMed ID: 6383417
[No Abstract] [Full Text] [Related]
15. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
Lum CT; Umen AJ; Kasiske B; Goerdt P; Heim-Duthoy KL; Andersen RC; Odland MD; Ney AL; Jacobs DM; Rao KV
Transplantation; 1995 Feb; 59(3):371-6. PubMed ID: 7871567
[TBL] [Abstract][Full Text] [Related]
16. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of T lymphocyte subset ratios for renal transplant survival in patients on different immunosuppressive regimens.
Henny FC; van Es A; Oljans PJ; Baldwin WM; Tanke HJ; van Es LA; Paul LC
Clin Exp Immunol; 1986 Aug; 65(2):373-80. PubMed ID: 3024886
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
Pescovitz MD; Book BK; Milgrom ML; Leapman SB; Petersen B; Filo RS
Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
[TBL] [Abstract][Full Text] [Related]
19. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
[TBL] [Abstract][Full Text] [Related]
20. Monitoring immunosuppression following renal transplantation.
Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
